BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,761 shares of the biopharmaceutical company's stock after purchasing an additional 2,678 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in Regeneron Pharmaceuticals were worth $14,789,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. CSS LLC IL bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $435,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after acquiring an additional 226,952 shares during the last quarter. Voloridge Investment Management LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $151,105,000. Waverly Advisors LLC increased its stake in Regeneron Pharmaceuticals by 23.0% in the fourth quarter. Waverly Advisors LLC now owns 1,280 shares of the biopharmaceutical company's stock valued at $912,000 after acquiring an additional 239 shares during the last quarter. Finally, Woodline Partners LP increased its stake in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Woodline Partners LP now owns 103,279 shares of the biopharmaceutical company's stock valued at $73,569,000 after acquiring an additional 3,862 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 1.4%

REGN traded down $8.51 during midday trading on Friday, hitting $588.34. The company had a trading volume of 655,734 shares, compared to its average volume of 801,377. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock's 50 day moving average price is $592.38 and its 200 day moving average price is $675.94. The company has a market capitalization of $63.52 billion, a price-to-earnings ratio of 15.37, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Bank of America cut their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. Finally, Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $890.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.